Sede Azogues - Medicina
URI permanente para esta comunidadhttps://dspace.ucacue.edu.ec/handle/ucacue/88
Examinar
Examinando Sede Azogues - Medicina por Asesores "Buenaño Rodriguez, Christian Eduardo"
Mostrando 1 - 2 de 2
- Resultados por página
- Opciones de ordenación
Ítem Acceso Abierto Eficacia de Infliximab versus Rituximab en el tratamiento de la artritis reumatoide: revisión sistemática(Universidad Católica de Cuenca., 2025) Minchala Castro, Mayra Isabbel; Buenaño Rodriguez, Christian Eduardo; 0302216791Optimal dosing of biologics for rheumatoid arthritis (RA) remains undefined, contributing to clinical variability. The objective was to evaluate the efficacy of Infliximab and Rituximab (bDMARDs) to identify dosing regimens that maximize outcomes and safety. A PRISMA 2020 systematic review was conducted in PubMed, Scopus, Web of Science, and Springer, focusing on studies from the last 10 years that met the ACR 20/50/70 criteria. Reviews, meta-analyses, and gray literature were excluded. The risk of bias was assessed using the RoB 2 tool. Infliximab 10 mg/kg every 8 weeks demonstrated the highest clinical response; 6 mg/kg provided a balance between efficacy and safety. Rituximab at 2 × 1000 mg reduced activity more than 2 × 500 mg, although the advantage was modest. Both therapies were administered with methotrexate to enhance the response. However, unrepresentative populations make broad extrapolation difficult. In conclusion, both drugs are viable therapies; infliximab is faster-acting, while rituximab is useful after prior treatment failures. The choice should be individualized, considering impact, cost, and tolerance to optimize quality of life. Keywords: Infliximab, Rituximab, dosing, effectivenessÍtem Acceso Abierto Inmunoterapia como tratamiento actual para Cáncer colorrectal. Revisión Sistemática(Universidad Católica de Cuenca., 2025) Aguilar Mora, Elian Alberto; Buenaño Rodriguez, Christian Eduardo; 0705621126Immunotherapy for colorectal cancer (CRC) has increased its development at an accelerated rate in the last 10 years. Several high-quality clinical trials have been conducted in the last decade to examine the application of programmed death receptor (1DPD-1) / programmed death ligand (PD-L1) inhibitors in patients with metastatic colorectal cancer (mCRC). However, the clinical benefits, including the effectiveness and safety of these anti-CCRCC managements, remain controversial. Objective: To analyze the efficacy of Pembrolizumab as immunotherapy in patients with colorectal cancer, using a systematic review. Methodology: In this study, a systematic review was conducted to determine the efficacy of immunotherapy as a modern treatment for CRC. Detailed searches were performed in several bibliographic databases, including PubMed, Taylor & Francis, Scopus, and ProQuest, among others, published until 2023. The search terms used were “metastatic colorectal cancer,” “immunotherapy,” “PD-1,” “PD-L1,” and study subjects at different stages of pathology were included. Relevant articles that met the established inclusion criteria were selected and analyzed. Results: Anti-PDL- 1/PD-1 (Pembrolizumab) therapy in advanced dMMR/MSI-H CRC was associated with improved survival. Anti PD-1/PD-L1 combined with anti-angiogenic drugs, targeted agents, or chemotherapy could be effective in MSS mCRC. Conclusions: Immunotherapy was effective for BRAF and KRAS/NRAS (RAS/RASRAS) mutated CRC. The high incidence of grade II and III adverse reactions at 85% reveals the importance of multidisciplinary work and further research and updates on this topic. Keywords: immunotherapy, metastatic colorectal cancer, PD-1, PD-L1, Pembrolizumab
